Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Am J Ophthalmol. 2011 Jun 12;152(2):266–272. doi: 10.1016/j.ajo.2011.01.053

Table 3.

Ocular complications after anti-VEGF treatment for neovascular AMD.

Ocular complication Control group
(n=6154 pts)
Number (%)		 Anti-VEGF treatment
group
(n=6154 pts)
Number (%)		 p-value Rate of
complication
per injection in
treatment group
(n=40903
injections)
%		 Rate of
complication
per injection in
treatment group
in excess of
observed rate in
control group
(n=40903
injections)
%
Endophthalmitis 6(0.10%) 38(0.62%) <.01** 0.09% 0.08%
Rhegmatogenous retinal detachment 40(0.65%) 41(0.67%) 0.9115 0.10% 0.002%
Retinal tear 17(0.28%) 24(0.39%) 0.2743 0.06% 0.02%
Uveitis 23(0.37%) 45(0.73%) <.01** 0.11% 0.05%
Vitreous hemorrhage 46(0.75%) 95(1.54%) <.01** 0.23% 0.12%
*

difference significant at the p≤0.05 level

**

difference significant at the p< 0.01 level